Ocaperidone
From Infogalactic: the planetary knowledge core
![]() |
|
Names | |
---|---|
IUPAC name
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one
|
|
Identifiers | |
129029-23-8 | |
ChemSpider | 64451 |
46 | |
Jmol 3D model | Interactive image |
KEGG | D02675 |
MeSH | C072259 |
PubChem | 71351 |
|
|
|
|
Properties | |
C24H25FN4O2 | |
Molar mass | 420.49 g·mol−1 |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
Infobox references | |
Ocaperidone (also R 79598) is a benzisoxazole antipsychotic.[1] It was initially developed by Janssen, later licensed to French laboratory Neuro3D and then acquired in 2007 by German company Evotec. Its testing was abandoned after phase II trials, as of 22 February 2010.[2]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
<templatestyles src="Asbox/styles.css"></templatestyles>